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Abstract: BACKGROUND: CCN1 is an evolutionary ancient matricellular protein that modulates biolog-
ical processes associated with tissue repair. Induction at sites of injury was observed in conditions ranging
from skin wounds to cardiac diseases, including ischemic and inflammatory cardiomyopathy. Here, we
provide evidence of a novel function of CCN1 as a modulator of immune cell migration. METHODS
AND RESULTS: to understand the role of CCN1 in cardiomyopathies and to evaluate its therapeu-
tic potential, we overexpressed CCN1 using an adenoviral hepatotropic vector in murine experimental
autoimmune myocarditis, a model of human inflammatory cardiomyopathy. CCN1 gene transfer sig-
nificantly reduced cardiac disease score and immune cell infiltration. In vivo tracking of hemagglutinin
epitope-tagged CCN1 revealed binding to spleen macrophages but not to cardiomyocytes. Unexpectedly,
CCN1 therapy left cardiac chemokine and cytokine expression unchanged but instead strongly inhib-
ited the migration of spleen macrophages and lymphocytes, as evidenced by ex vivo transwell assays.
In accordance with the ex vivo data, in vitro preincubation with CCN1 diminished transwell migration
of human monocytes and abrogated their chemotactic response to monocyte chemoattractant protein-
1, macrophage inflammatory protein-1￿, and stromal cell-derived factor-1￿. Further mechanistic studies
showed that CCN1-driven modulation of immune cell migration is mimicked in part by cyclic RGD pep-
tides currently in clinical evaluation for cancer therapy. CONCLUSIONS: our proof-of-concept study
suggests investigation of CCN1 as a novel, endogenous ”parent compound” for chemotaxis modulation
and of cyclic RGD peptides as a class of partially CCN1-mimetic drugs with immediate potential for
clinical evaluation in cardiac diseases associated with chronic pathogenic inflammation.
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Heart Failure
Matricellular Signaling Molecule CCN1 Attenuates
Experimental Autoimmune Myocarditis by Acting as a
Novel Immune Cell Migration Modulator
Madlen Rother, MSc*; Stefanie Krohn, MSc*; Gabriela Kania, PhD; Davy Vanhoutte, PhD;
Andreas Eisenreich, PhD; Xiaomin Wang, MSc; Dirk Westermann, MD; Kostas Savvatis, MD;
Nadine Dannemann, MSc; Carsten Skurk, MD; Denise Hilfiker-Kleiner, PhD; Toni Cathomen, PhD;
Henry Fechner, DVM; Ursula Rauch, MD; Heinz-Peter Schultheiss, MD; Stephane Heymans, MD;
Urs Eriksson, MD; Carmen Scheibenbogen, MD*; Wolfgang Poller, MD*
Background—CCN1 is an evolutionary ancient matricellular protein that modulates biological processes associated with
tissue repair. Induction at sites of injury was observed in conditions ranging from skin wounds to cardiac diseases,
including ischemic and inflammatory cardiomyopathy. Here, we provide evidence of a novel function of CCN1 as a
modulator of immune cell migration.
Methods and Results—To understand the role of CCN1 in cardiomyopathies and to evaluate its therapeutic potential, we
overexpressed CCN1 using an adenoviral hepatotropic vector in murine experimental autoimmune myocarditis, a model
of human inflammatory cardiomyopathy. CCN1 gene transfer significantly reduced cardiac disease score and immune
cell infiltration. In vivo tracking of hemagglutinin epitope–tagged CCN1 revealed binding to spleen macrophages but
not to cardiomyocytes. Unexpectedly, CCN1 therapy left cardiac chemokine and cytokine expression unchanged but
instead strongly inhibited the migration of spleen macrophages and lymphocytes, as evidenced by ex vivo transwell
assays. In accordance with the ex vivo data, in vitro preincubation with CCN1 diminished transwell migration of human
monocytes and abrogated their chemotactic response to monocyte chemoattractant protein-1, macrophage inflammatory
protein-1, and stromal cell–derived factor-1. Further mechanistic studies showed that CCN1-driven modulation of
immune cell migration is mimicked in part by cyclic RGD peptides currently in clinical evaluation for cancer therapy.
Conclusions—Our proof-of-concept study suggests investigation of CCN1 as a novel, endogenous “parent compound” for
chemotaxis modulation and of cyclic RGD peptides as a class of partially CCN1-mimetic drugs with immediate
potential for clinical evaluation in cardiac diseases associated with chronic pathogenic inflammation. (Circulation.
2010;122:2688-2698.)
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Progressive dilation and dysfunction of heart chambers,wall thinning, and tissue fibrosis are typical of dilated
cardiomyopathy, a common final pathway of heart failure that
results from different causes, including monogenic defects
in cardiac-expressed genes and exogenous factors such
as cardiotoxic drugs or cardiotropic viruses. Inflammatory
cardiomyopathy represents an important subtype of dilated
cardiomyopathy and may be caused by cardiotropic virus–
dependent processes or virus-triggered heart-specific autoim-
munity. Cardiac expression profiling revealed that an
inflammation-related gene network is strongly altered in
patients with inflammatory cardiomyopathy compared with
normal hearts.1 This network includes the matricellular pro-
tein CCN1 (Cyr61), 2 other members of the CCN protein
family (CTGF and WISP-1),2,3 and the 2 CCN1-interacting
proteins, thrombospondin-1 and 1-integrin, which also mod-
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ulate tissue repair.4,5 To date, CCN1, a member of a gene
family with 6 known members, has been characterized
functionally mainly in vitro. In cell cultures, it acts in a cell
type– and context-dependent manner through binding to
several integrins,6–9 including 61, v3, v5, and M2, as
well as to heparan sulfate proteoglycans.10,11 CCN1 is in-
volved in integrin-linked kinase–mediated AKT and
-catenin–T-cell factor/Lef signaling12 and stem cell differ-
entiation.13 Several lines of evidence suggest that CCN1 plays
an important role in wound healing in vivo. We have
previously shown that it is locally upregulated in ischemic14
and inflammatory1 cardiomyopathy in humans. During
wound healing,15 it coordinates a pattern of genes that
promote extracellular matrix remodeling, cytokine induction,
and angiogenesis, all of which are required for proper repair
of tissue architecture.
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Here, we provide for the first time evidence for a novel
function of locally produced CCN1 acting as an immune
signaling molecule at distant sites. To better understand the
immunologic role of this novel function in the context of
inflammatory heart disease and to evaluate its potential
therapeutic efficacy, we used a gene-transfer approach to
overexpress CCN1 in mice and assessed their susceptibility to
experimental autoimmune myocarditis (EAM).16–20 In previous
studies of the EAM model, it has been shown that myosin-
specific CD4 T-cell responses result in macrophage inflamma-
tory protein-1 (MIP-1)– and monocyte chemoattractant
protein-1 (MCP-1)–driven recruitment of CD11b monocytes
to the inflamed myocardium. Blockade of MIP-1 and MCP-1
by antibodies or a dominant-negative protein significantly re-
duced disease severity.21 Unexpectedly, in the present study,
CCN1 overexpression reduced EAM disease scores and cardiac
immune cell infiltrations without changing cardiac chemokine or
chemokine receptor expression but directly inhibited the migra-
tion of circulating immune cells. CCN1 gene transfer (as used in
the present proof-of-concept study), recombinant CCN1 protein,
or CCN1-mimetic drugs, including cyclic RGD peptides
(cRGDs), may have therapeutic potential in cardiac diseases
associated with chronic pathogenic inflammation.
Methods
Cell Culture and Proteins
Peripheral blood mononuclear cells of healthy human donors (men
and women 25 to 50 years old) were cultivated in Iscove’s modified
Dulbecco’s medium supplemented with 10% AB serum. The study
was reviewed and approved by the Institutional Ethics Committee,
and informed consent was obtained from the patients. The proteins
stromal cell–derived factor-1 (SDF-1; R&D Systems, Minneap-
olis, Minn), MCP-1 (Invitrogen, San Diego, Calif), MIP-1 (Invitro-
gen), and CCN1 (Cell Sciences, Canton, Mass) were used at 200
ng/mL for stimulation. cRGD peptide (H4772; Bachem, Bubendorf,
Switzerland) was used at 10 mol/L for preincubation.
Development of Adenoviral CCN1 Vectors
Murine CCN1 complementary DNA (cDNA) was amplified from
pAdTrack-CMV (nucleotide sequence NM_010516 [nucleotide 194-
1333]) and cloned into the adenovector transfer plasmid pZS2. The
recombinant plasmid was ligated to the long arm of the adenovirus
strain RR5 as described previously,22,23 and the product was trans-
fected into HEK293 cells; a recombinant adenoviral clone, AdV-
CMV-mCCN1, was amplified and purified by CsCl ultracentrifuga-
tion. For hemagglutinin epitope (HA)-tagged CCN1 vector, CCN1
cDNA was amplified from mouse muscle RNA and cloned into the
pRK5 plasmid. Further cloning steps into pJet1.2 (Invitrogen) and
pRK5d followed, and CCN1-HA was finally cloned into the ad-
enovector transfer plasmid pZS2.
CCN1 Vector Evaluation in Cell Cultures
EA.hy926 cells were transduced with AdV-CMV-mCCN1, 5103
particles/cell. After 72 hours, cell lysate and supernatants were collected
and analyzed by Western blots under reducing conditions with an
-mouse-CCN1 primary antibody (R&D Systems) and a secondary
horseradish peroxidase antibody (Dako, Glostrup, Denmark).
CCN1 Gene Transfer In Vivo
For the murine autoimmune myocarditis model, either AdV-CMV-
mCCN1 or RR5, 31010 particles/mouse, was injected via tail vein
into female BALB/c mice 1 week before immunization with myosin
heavy chain- (MyHC-). AdV-CMVmCCN1-HA vector or RR5
was injected intravenously in the same doses into 10-week-old mice.
For the murine myocardial infarction (MI) model, AdV-CCN1 or
AdV-RR5 was also injected intravenously into male C57B/6 mice 4
days before MI induction.
Analysis of Circulating CCN1 Protein
Circulating CCN1 was studied by Western blot (see “CCN1 Vector
Evaluation”) of mouse sera after albumin depletion. The resulting pellet
was finally resuspended with 8 mol/L urea, 2 mol/L thiourea.24
Circulating CCN1 in heparin plasma from AdV-CCN1-HA–treated,
RR5-treated, or nontreated mice was analyzed by ELISA (DGR Diagnos-
tics, Marburg, Germany) according to the manufacturer’s instructions.
Tracking of Ad-CCN1-HA In Vitro and Ex Vivo
EA.hy926 cells were transduced with 5103 particles/cell of vector
AdV-CMV-mCCN1-HA. Brefeldin A was added after 48 hours at 7.5
ng/mL for intracellular fluorescent-activated cell sorter (FACS) staining.
After 72 hours, cells were harvested and stained with -HA-fluorescein
isothiocyanate (-HA-FITC; Miltenyi Biotech, Bergisch Gladbach,
Germany). Livers, spleens, hearts, and peripheral blood mononuclear
cells generated by Ficoll gradient from AdV-CCN1-HA–transfected or
nontransfected mice were taken on day 25. Single-cell suspensions were
analyzed by flow cytometry with a FACS Canto II analyzer (Becton
Dickinson, Franklin Lakes, NJ) and -HA-FITC antibody or -mouse-
IgG1 isotype control (Miltenyi Biotech). Surface staining was done for
extracellular molecules CD11b, CD3e, CD11c, B220, and pan NK cells,
respectively (eBioscience, San Diego, CA).
Induction of Murine Autoimmune Myocarditis
Vectors were injected intravenously 1 week before the immuniza-
tion, and then female BALB/c mice were immunized with 100 g of
MyHC-/complete Freund’s adjuvant on days 0 and 7. Control mice
received MyHC-/complete Freund’s adjuvant only. All analyses
were performed at the peak of inflammation 21 days after immuni-
zation with MyHC-/complete Freund’s adjuvant. Myocarditis se-
verity score was assessed on hematoxylin-and-eosin–stained sections
graded 0 to 4 according to a semiquantitative score (0, no inflam-
matory infiltrates; 1, small foci of inflammatory cells between
myocytes; 2, larger foci of 100 inflammatory cells; 3, 10% of a
cross section involved; and 4, 30% of a cross section involved).
Induction and Analysis of Murine MI
MI was induced by coronary artery ligation as described previously,25
and mice were killed 14 days later (8 animals per group). Infarction
was evident from discoloration of the left ventricle. For histological
analysis, hearts were fixed and sectioned (4 m), and CD45 staining
was performed to evaluate the number of leukocytes that had
infiltrated the infarcted left ventricle. The number of CD45 cells in
the infarcted area was counted per square millimeter, and residual
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necrotic area (characterized by the presence of necrotic cells without
evidence of local clearance, collagen deposition, or fibrosis) was
calculated planimetrically as a percentage of the total infarct area.
RNA Analyses
Mice were injected with the vector AdV-mCCN1 or RR5 or left
untreated. Mouse livers were analyzed on days 10, 20, and 40 by
Northern blots and hybridized with a probe selective for recombinant
mouse CCN1 (mCCN1) mRNA. For quantification versus -actin,
Scion Image Gelplot2 software (Scion Corporation, Frederick, Md)
was used. Total RNA extraction and reverse-transcription reac-
tion and real-time polymerase chain reaction were performed with
mouse hearts to analyze mRNA expression levels of interferon-,
interleukin-17A, MIP-1, and MCP-1, respectively.
Migration Assays With Mouse Primary Cells
Single-cell suspensions were made from the spleens of RR5- or
CCN1-transfected BALB/c mice. Erythrocytes were lysed with ACK
buffer. Splenocytes were added to the upper well, and cells in the
lower chamber were harvested after 24 hours of transmigration in an
8-m 96-well plate (Corning, Corning, NY); stained for CD11b and
CD3e, respectively; and resuspended in 100 L of PBS plus 2%
Flebogamma. A 30-L 1:10 dilution of polystyrol beads (Comp
Beads, negative control; BD, San Jose, Calif) was added to each
approach. Counting was performed by FACS analysis by gating on
the bead population and uptake of exactly 20 000 beads per ap-
proach. The increase was estimated as the ratio to samples without
stimulation. Dead cells were estimated by a gating strategy.
Migration Assays With Human Primary Cells and
THP-1 Cells
MCP-1, MIP-1, or CCN1 was added to the lower wells of a
transwell plate that contained medium plus 10% serum. Next,
1.5105 peripheral blood mononuclear cells from healthy human
donors purified by Ficoll gradient were suspended in culture medium
plus 10% AB serum and added to the upper well for 24 hours. Cells
in the lower chamber were harvested, stained with anti-CD14 antibody
(BD Pharmingen), and counted as described for mouse primary cells. In
preincubation experiments, cells were stimulated with CCN1 for 24
hours, then washed and restimulated as described above. Furthermore,
experiments were performed with negatively magnetic-activated cell–
sorted CD3 T cells and adhesion-enriched monocytes from human
peripheral blood mononuclear cells. After transwell migration of
THP-1, cells in the lower chamber were not harvested but were
incubated with MTT (tetrazolium bromide) 5 mg/mL (Sigma, Munich,
Germany) in a 1:10 dilution for 4 hour sat 37°C. Next, 0.04N HCl in
isopropanol was added 1:1 into the lower well to dissolve the dark blue
crystals. Plates were read at a wavelength of 570 nm against a blank
without cells, and migration was calculated as the ratio to unstimulated
cells. Cells were stimulated as indicated.
Western Blot Analyses
Thirty micrograms of THP-1 cell lysate was used for Western blots
under denaturing and reducing conditions and transferred to a
polyvinylidene fluoride membrane (Bio-Rad, Hercules, Calif). Mem-
branes were incubated with the primary antibodies -GAPDH
(Millipore, Billerica, Mass), -Nck2 (Abnova, Neihu District, Taipei
City, Taiwan), and -PINCH, -ILK, AKT, and pAKTS472/473 (BD
Biosciences), as well as the secondary antibody Ig-HRP (Dako).
Antibodies were incubated for 1 hour or overnight in Tris-buffered
saline with Tween with 5% dry milk. For detection, a Rodeo ECL
Western blot detection kit (USB Corp, Cleveland, Ohio) was used.
Chemokine Receptor Expression
Peripheral blood mononuclear cells were either left untreated or were
stimulated with recombinant human CCN1 protein at 200 ng/mL for
24 hours. Cells were harvested; stained extracellularly for CCR2,
CCR5, and CXCR4, respectively; and then analyzed by gating for
lymphocyte and monocyte populations by FACS to compare median
fluorescence intensities.
Statistical Analyses
Statistical data analyses were performed with SPSS 18.0 (SPSS Inc,
Chicago, Ill). Nonparametric statistical methods were used. Contin-
uous variables are expressed as median and interquartile range unless
otherwise indicated. Univariate comparisons of 2 independent
groups were performed with the Mann–Whitney U test. Confirma-
tory analyses relative to 2 groups were performed with the
Kruskal-Wallis test followed by post hoc testing via Mann–Whitney
U test with Bonferroni adjustment for multiple testing. To compare
between 2 paired groups, the Wilcoxon signed rank test was applied.
Because of the small sample sizes, calculations were performed with
exact assumption methods (option “exact” in SPSS 18.0). A 2-tailed
P value of P0.05 was considered statistically significant. For
further details, see the online-only Data Supplement.
Results
Overexpression and Tracking of Recombinant
CCN1 Protein In Vivo
Multiple cell types synthesize CCN1 protein, but in contrast
to common secreted proteins, CCN1 has high affinity for
extracellular matrix proteins,26 and steady state levels of
endogenous CCN1 are low in the circulation. Because quan-
tification of plasma levels27 cannot reveal the kinetics of
locally produced CCN1 in the circulation, we decided to
perform in vivo tracking experiments of recombinant HA-
tagged protein. For this purpose, 2 cDNAs expressing native
full-length mCCN1or a variant thereof (mCCN1-HA) with a
carboxy-terminal 9–amino acid HA tag (the hemagglutinin
epitope YPYDVPDYA from influenza virus A) were cloned
into the hepatotropic adenovirus mutant RR5 to yield the
vectors AdV-mCCN1 and AdV-mCCN1-HA, respectively
(Figure 1A). When AdV-mCCN1 or AdV-mCCN1-HA is
expressed in EA.hy926 cells, a major fraction of CCN1
remains cell-bound, but there is free full-length CCN1 protein
and an expected 21-kDa plasmin degradation product28 in the
cell supernatants (Figure 1B). By intracellular flow cytom-
etry, recombinant CCN1 protein could be detected both
intracellularly and on the surface of EA.hy926 cells (Figure
1C). In contrast to recombinant CCN1 mRNA, which carries
a vector-derived bovine growth hormone (bGH) sequence at
its 3-end, endogenous CCN1 transcripts lack this sequence
and therefore do not hybridize to a radioactive bGH probe as
used for the Northern blot analyses shown in Figure 1D.
CCN1 gene transfer by intravenous injection of vector into
mice resulted in liver-specific expression of the recombinant
CCN1 mRNA over several weeks (Figure 1D). Vector
tropism may change owing to disease-associated processes,
but Northern blot analysis of EAM and post-MI hearts did not
detect vector genome within the diseased hearts. Flow cy-
tometry revealed no binding of recombinant liver-derived
HA-tagged CCN1 protein to cardiac or liver cells but did
reveal strong binding to spleen and blood CD11b cells
(Figure 1E), consistent with a report demonstrating M2
integrin as a CCN1 receptor on monocytes.8 Because adeno-
viral gene transfer is highly liver-selective, with99% of the
vector located and expressed in this organ, the detection of
HA-tagged protein on macrophages proves secretion of re-
combinant CCN1 protein and binding to immune cells.
Furthermore, CCN1 protein could be detected by Western
blot analysis in sera with 50- to 42-kDa bands corresponding
to glycosylated full-length CCN1, an unglycosylated form,
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and a 21-kDa plasmin degradation fragment,28 respectively
(Figure 1F). ELISA detected high CCN1-HA levels in hep-
arin plasma from AdV-CCN1-HA–treated mice compared
with RR5-treated or nontreated mice (Figure 1E). Taken
together, these data show that hepatic overexpression of
CCN1 vector results in a circulating CCN1 pool with binding
to macrophages at distant sites.
Systemic CCN1 Therapy Attenuates EAM
To evaluate the effect of systemic CCN1 overexpression in
EAM, mice were injected intravenously with CCN1 or
control vector 1 week before immunization with MyHC-,
which induces EAM. As shown in Figure 2A and 2B, CCN1
treatment of mice resulted in a significant reduction of the
histological disease severity scores compared with controls in
hearts analyzed at the peak of cardiac inflammation 3 weeks
after immunization. Because EAM leads to a strong upregu-
lation of various cytokines and chemokines, with the
monocyte-attracting chemokines MIP-1 and MCP-121 and
interleukin-17A playing crucial roles,20 we specifically ad-
dressed the influence of CCN1 on expression of MIP-1 and
MCP-1, as well as the T-cell cytokines interleukin-17A and
interferon-, in the diseased hearts. However, no change in
the expression of these (Figure 2C) or various other chemo-
Figure 1. Overexpression and tracking of recombinant CCN1 protein in vivo. A, Recombinant adenoviral vector AdV-mCCN1 was gen-
erated by cloning of a full-length mouse CCN1 cDNA into the transfer plasmid pZS2, followed by its ligation to the long arm of adeno-
virus mutant RR5. AdV-mCCN1-HA expresses the 379–amino acid CCN1 linked to a carboxy-terminal 9–amino-acid hemagglutinin
epitope (HA) tag (YPYDVPDYA from influenza virus A). Both vectors are under control of a cytomegalovirus (CMV) promoter and con-
tain a bovine growth hormone termination signal (bGH), which was used in Northern blots (D) to distinguish endogenous from exoge-
nous CCN1 mRNA. B, AdV-mCCN1–transduced EA.hy926 cells showed a 40-kDa band (representing CCN1) in the cell lysates, as
shown in lanes 5/6 of the Western blot. Lysates of untreated (NT; lanes 1/2) or control vector–treated (RR5; lanes 3/4) cells showed no
CCN1-specific band. In the supernatants, a full-length 40-kDa protein and a 21-kDa fragment were detected in AdV-mCCN1–trans-
duced cells (lanes 9/10; 2 parallel samples from independent cell cultures). Lane 7 shows supernatants from a nontreated culture, and
lane 8 shows supernatants from an RR5 control vector–treated cell culture. C, EA.hy926 cells transduced with AdV-mCCN1-HA were
analyzed by flow cytometry to assess the distribution of the recombinant HA-tagged CCN1 protein between the intracellular compart-
ment and the cell membrane. The red curve shows nontransfected cells, and the blue curve represents CCN-HA–transfected cells (1 of
2 independent experiments). D, Northern blot analysis of recombinant CCN1 in mouse livers shows the stability of AdV-mCCN1 expres-
sion in vivo after intravenous administration of 31010 vector particles/animal. Parallel samples from 3 nontreated animals (NT) and
from AdV-CCN1–treated animals (CCN1) and mice that received control vector (RR5) are shown on days 10, 20, and 40 after vector
injection (n2 to 3). The blots were hybridized with a probe that detected the bGH termination sequence of recombinant CCN1 only
(upper blot). Quantification vs -actin is shown in the graph. E, Flow cytometric analysis of mice treated with AdV-mCCN1-HA showed
no HA-tagged protein bound to the cell membrane of cardiac and hepatic cells in animals treated with CCN1-HA vector (blue curve)
compared with control mice (red curve) 3 weeks after gene transfer. Membrane bound HA-tagged protein was detected in splenic and
blood CD11b cells by use of an -HA antibody (1 of 2 independent experiments). Circulating CCN1 plasma levels (shown as median)
of AdV-mCCN1-HA–treated mice (n8) were analyzed by ELISA and compared with those of RR5-treated (n4) and nontreated mice
(n4), respectively, on days 14 and 21 after vector injection. F, Five weeks after AdV-mCCN1 vector injection, Western blot analysis of
mouse sera, after ethanol precipitation of serum albumin, showed mCCN1-specific bands that corresponded to glycosylated full-length
CCN1 (50 kDa), an unglycosylated form at 40 kDa, and an NH2-terminal plasmin degradation fragment at 21 kDa28 (n2).
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kines and chemokine receptors (data not shown) were ob-
served. Subsequently, the migratory potential of splenic
immune cells from treated animals was compared ex vivo in
transwell migration assays. Remarkably, splenocytes from
CCN1 vector–treated EAM mice showed strongly reduced ex
vivo migration of both CD3e T cells and CD11b macro-
phages compared with controls (Figure 2D). An apoptosis-
enhancing effect of CCN1 was excluded (Figure 2E).
To determine whether immune cell migration blockade as
observed in EAM animals would occur only in this specific
disease model, we investigated the influence of CCN1 gene
transfer in MI in mice. As shown in Figure 3A and 3B, one
effect common to the EAM and MI model was the suppres-
sion of cardiac immune cell infiltration. In the MI model, this
suppression of cardiac inflammation was associated with
diminished removal of necrotic cardiomyocytes 14 days after
MI, as shown by a significantly reduced residual necrotic area
in Figure 3C and 3D. No influence on cardiac fibrosis or infarct
thickness was observed (data not shown). Taken together, these
data imply that CCN1 therapy does not inhibit cardiac immune
Figure 2. Systemic CCN1 therapy attenuates experimental autoimmune myocarditis. A, CCN1 or RR5 control vectors were injected in-
travenously 1 week before immunization of mice with a 1:1 emulsion of 100 g/mouse MyHC- (myosin heavy chain-) peptide
together with complete Freund adjuvant (CFA). Histological analysis by hematoxylin-and-eosin staining showed leukocyte infiltration of
mouse hearts 3 weeks after the second immunization. Cardiac immune cell infiltration was greatly reduced in the hearts of mice treated
with the adenoviral vector AdV-mCCN1 compared with RR5-treated mice (2 representative examples from 2 independent experiments).
B, Myocarditis severity was assessed on hematoxylin-and-eosin–stained sections and graded by a semiquantitative score from 0 to 4
(0, no inflammatory infiltrates; 1, small foci of inflammatory cells between myocytes; 2, larger foci of 100 inflammatory cells; 3, 10%
of a cross section involved; and 4, 30% of a cross section involved). The disease severity scores were significantly (**P0.01, Mann–
Whitney U test for independent samples) reduced by AdV-mCCN1 vector treatment (CCN1, n10) compared with control vector–
treated animals (RR5, n12); median scores are shown. C, Real-time polymerase chain reaction analysis was performed for hearts of
nontreated mice (NT), mice that had received MyHC-/CFA alone (n6), and mice that had received MyHC-/CFA (n6) with either
AdV-mCCN1 (n10) or RR5 vector (n12). Expression of interferon- (IFNg), interleukin-17A (IL-17A), macrophage inflammatory
protein-1 (MIP-1), and monocyte chemoattractant protein-1 (MCP-1) was calculated as the expression level compared with
Hypoxanthine-Guanine-Phosphoribosyltransferase. There was no significant reduction (shown as meanSEM) of chemokine or cytokine
expression levels in AdV-CCN1–treated mice vs RR5-treated mice. Hearts were taken at the peak of inflammation. n.s. indicates not
significant (Mann–Whitney U test for independent samples); n.d., not detected. D, Migration assays of splenocytes isolated from mice
at peak inflammation, 3 weeks after the second immunization, showed significantly (**P0.01, Mann–Whitney U test for independent
samples) reduced migration of both CD11b macrophages (left) and CD3e T cells (right) in AdV-CMV-CCN1–treated animals (n6)
compared with RR5-treated controls (n6) in culture medium that contained serum after 24 hours (values shown as medians). E, Viabil-
ity of splenocytes during CCN1 therapy was assessed by fluorescent-activated cell sorter gating strategy. There was no difference in
absolute numbers (not shown) or frequency of dead splenocytes ex vivo after the migration assay of mice treated with CCN1 (n6) or
RR5 (n7) vector. n.s. indicates not significant (Mann–Whitney U test for independent samples).
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cell infiltration by acting on chemokine or cytokine release
within the heart but by direct inhibition of immune cell migra-
tion, and this effect on immune effector cells was the most
prominent finding in 2 different disease settings.
Preincubation With CCN1 Inhibits Immune Cell
Migration In Vitro
To further elucidate the mechanism of inhibition of immune
cell migration by CCN1, we performed in vitro experiments
on freshly isolated human immune cells. Consistent with the
ex vivo data from EAM mice on CCN1 therapy, in which
CCN1 serum levels were chronically elevated, in vitro
preincubation with CCN1 significantly diminished the sub-
sequent transwell migration of CD14 monocytes (Figure
4A). Although short-term exposure to CCN1 in transwell
migration assays resulted in enhanced migration of human
primary CD14 monocytes and CD3 lymphocytes (data not
shown), significantly extending the spectrum of cells previously
known to be influenced by CCN1,6,8–10,27 in vitro preincubation
with CCN1 over 24 hours completely abolished subsequent
transwell migration of CD14 monocytes in response to CCN1.
Of note, CCN1 preincubation left the CD14 cells refractory not
only to rechallenge with CCN1 but also to chemotactic stimu-
lation by MCP-1 and MIP-1 (Figure 4B). A similar CCN1
effect was seen for isolated negatively sorted CD3 T-cell and
monocyte populations (Figure 4D). No changes in chemokine
receptor expression were detected for either monocytes or
lymphocytes (Figure 4E).
Similar to human primary CD14 cells, the human mono-
cytic cell line THP-1 became refractory to chemotactic
stimulation by MCP-1, MIP-1, and SDF-1 after CCN1
preincubation (Figure 4C). As shown in Figure 4F, immuno-
blot quantitation of the expression levels of ILK (integrin-
linked kinase), NCK2, PINCH (particularly interesting new
cysteine-histidine–rich protein), and AKT, proteins involved
in integrin signaling,12,29 revealed no significant changes
induced by CCN1 preincubation. mRNA expression levels of
the -subtype of phosphoinositide 3-kinase, the target of a
new class of antiinflammatory drugs,30 and of matrix metal-
loproteinases 2 and 9 were likewise unchanged (data not
shown). Figure I in the online-only Data Supplement com-
pares the chemotaxis-modulating effect of CCN1 preincuba-
tion with those of drugs that block all phosphoinositide
3-kinases,31 the phosphoinositide 3-kinase- subtype only,30
AKT,32 Rho kinase,33 or MEK (mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase).31 CCN1
preincubation blocked the effect of all chemotactic stimuli
(CCN1, SDF-1, MCP-1, and MIP-1), whereas the spec-
trum of action of the small-molecule drugs was more limited.
cRGD Peptides Are Partially CCN1-Mimetic Drugs
CCN1 exerts several of its functions by binding to integrins
expressed on immune cells, although various heparan sulfate
proteoglycans are also involved in further cellular effects of
CCN1.10,11,34,35 Integrin targeting is currently developed for
cancer therapy,29 including the use of synthetic cRGD pep-
tides.36 Given their similarities with respect to integrin binding,
we therefore sought to compare the effects of a cRGD peptide
with those of CCN1 to further elucidate the potential role of
integrins for chemotaxis modulation by CCN1, with the under-
standing that these synthetic compounds bind selectively to a
few integrins of the v -type, whereas CCN1 binds to a larger
spectrum of integrins and heparan sulfate proteoglycans by use
of multiple and different binding sites.
Nevertheless, comparison of a cRGD peptide with CCN1
showed that preincubation with cRGD peptide also blocked
migration toward CCN1, MCP-1, and SDF-1 significantly
(Figure 5A). Dose-response experiments confirmed the inhib-
itory effect of cRGD preincubation on THP-1 cell migration
over a wide dose range from 0.1 to 100 mol/L. The
inhibitory effect of cRGD peptide on the migration toward
SDF-1 appeared to be less pronounced than that of CCN1
(Figure 5B). Taken together, the data suggest that integrin
targeting by different agents including CCN1 and cRGD
peptides may modulate immune cell chemotaxis migration,
although cRGD peptides bind to fewer integrins and appear to
have more limited effects than CCN1.
Discussion
CCN1 Gene Transfer Attenuates
Cardiac Inflammation
In contrast to a wealth of data on the effects of CCN1 in vitro,
data on its physiological functions in vivo are sparse, and its
therapeutic potential against cardiovascular diseases has not
yet been addressed. One limitation of in vitro studies of
CCN1 stems from the fact that the functions of this protein
may be profoundly altered by multiple factors not commonly
Figure 3. CCN1 attenuates cardiac inflammation after myocar-
dial infarction. A and B, CD45 cell immunostaining of the heart
on day 14 after myocardial infarction showed a significant
reduction of cell infiltrates in CCN1-treated (n7) compared with
RR5-treated (n8) mice. A shows typical examples of the
CD45 immunostaining, whereas B shows the statistical evalua-
tion for all animals, expressed as infiltrating cells per square mil-
limeter of fibrotic area. Magnification 40. *P0.05. C and D,
Histological analysis showed significantly increased areas of
residual necrotic cardiomyocytes (indicated by yellow arrows)
in CCN1-treated compared with RR5-treated mice. Magnifica-
tion 40. *P0.05 (Mann–Whitney U test for independent sam-
ples). C shows typical examples of the histological analysis,
whereas D shows the statistical evaluation for all animals,
expressed as residual necrotic area.
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present in vitro. These include numerous interacting proteins,
homodimerization via CT domains, and multimer formations
via VWC domains.34,35 Although isolated functions of the 4
CCN domains have been clarified to a considerable degree at
the molecular and cellular level, the complexity of their
known molecular interactions makes it impossible to predict
their overall effect in the intact organism. A CCN1 knockout
model has provided important data on functions during
development,37 but for the adult organism, CCN1 protein
tracking and modulation in disease models is likely to
contribute to a more comprehensive picture of its functions.
Using this approach, we obtained direct evidence of a
novel in vivo function of CCN1 acting as an inhibitor of
immune cell chemotaxis and migration. In an initial series of
experiments, tracking of recombinant CCN1 protein in vivo
showed that hepatic CCN1 overexpression resulted in a
circulating CCN1 pool that bound to splenic macrophages
and blood monocytes. In a second set of experiments, we
Figure 4. Preincubation with CCN1 inhibits immune cell migration in vitro. A, Basal migration (cell numbers) of freshly isolated human
CD14 cells (n12) was significantly (**P0.01, Wilcoxon signed rank test for dependent samples) reduced during migration in culture
medium that contained 10% serum for cells that were preincubated with CCN1 at 200 ng/mL for 24 hours compared with CD14 cells
from the same donor that were not preincubated. B, Prolonged CCN1 exposure (CCN1 24h Pre) resulted in abrogation of the
chemotaxis-stimulating effects of CCN1 itself and of the chemokines monocyte chemoattractant protein-1 (MCP-1) and macrophage
inflammatory protein-1 (MIP-1; black bars). After 24 hours of preincubation with 200 ng/mL CCN1, the chemokines were no longer
able to stimulate monocyte chemotaxis (gray bars). n9. P values on top indicate Kruskal-Wallis test results for the 3 experimental
groups (for chemokines CCN1, MCP-1, and MIP-1), each comprising cells with or without preincubation or with medium control.
Asterisks indicate significant effects of preincubation at the corrected significance level corr0.0167, with Pcorr0.05 (*) and
Pcorr0.001 (***), respectively, according to the Mann–Whitney U test for independent samples with Bonferroni adjustment for multiple
testing. Compare this in vitro finding with the ex vivo data shown in Figure 2D. C, Similar to the situation with primary human mono-
cytes, monocytic THP-1 cells were stimulated with 200 ng/mL CCN1, SDF-1), MCP-1, and MIP-1 for 24 hours with (gray bars) and
without (black bars) 24-hour 200-ng/mL CCN1 preincubation (CCN1 24h Pre). n9/10. P values on top indicate Kruskal-Wallis test
results for the 4 experimental groups (for chemokines CCN1, SDF-1, MCP-1, MIP-1), each comprising cells with or without preincu-
bation or with medium control. Asterisks indicate significant effects of preincubation on the corrected significance level corr0.0167,
with Pcorr0.001 (***) according to Mann–Whitney U test for independent samples with Bonferroni adjustment for multiple testing. D,
Migration experiments were performed with negatively magnetic-activated cell–sorted CD3 T cells (untouched; left) and adhesion-
enriched monocytes (right) from human peripheral blood mononuclear cells. n4 donors. P values on top of the left and right panels
indicate Kruskal-Wallis test results for the 2 experimental groups (sorted CD3 T cells, adhesion-enriched monocytes), each comprising
cells with or without preincubation or with medium control. CCN1 stimulation itself led to enhanced migration of both CD3 T cells and
monocytes (black bars), but CCN1 preincubation for 24 hours (CCN1 24h Pre) led to impaired migration (gray bars). E, Median fluores-
cence intensities in peripheral blood mononuclear cells were measured to quantify extracellular expression of chemokine receptors
CCR2, CCR5, and CXCR4 after 24 hours of CCN1 stimulation at 200 ng/mL and compared with unstimulated cells from the same
donor by extracellular staining (n6; Mann–Whitney U test for independent samples). F, Intracellular signal transduction proteins linked
to integrins and AKT phosphorylation were analyzed by Western blot analysis. Left side of each blot shows protein expression levels of
integrin-linked kinase (ILK), Nck2, PINCH (particularly interesting new cysteine-histidine–rich protein), and -arrestin 2, which blocks
G-protein–mediated signaling, at various time points (5 minutes, 30 minutes, 3 hours, 8 hours, and 24 hours) after addition of MCP-1
200 ng/mL. Blots on the right side show the same analyses but with addition of MCP-1 after a preceding preincubation with CCN1 at
200 ng/mL for 24 hours (1 of at least 2 independent experiments). Densitometric analysis (online-only Data Supplement Figure II)
showed, as expected, that MCP-1 induced upregulation of ILK, -arrestin, PINCH, and pAKTS472/473, but it detected no inhibitory effect
of 24-hour CCN1 preincubation on these inductions. IQR indicates interquartile range.
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found that chronic overexpression of CCN1 ameliorated the
course of EAM, a local autoimmune-triggered inflammation
associated with severe cardiac injury. Unexpectedly, CCN1
gene therapy did not modulate cardiac expression of the
chemokines MCP-1 and MIP-1 or of interleukin-17A,
which are known to be key mediators of EAM.20,21 Instead,
direct ex vivo analysis of circulating immune cells from mice
during CCN1 gene therapy revealed that their migratory
capacity ex vivo was greatly reduced. Although inhibition of
migration of vascular smooth muscle cells by CCN5 has been
described,38 CCN1 has so far been solely considered as a
protein that stimulates cell migration. In accordance with its
described effect on fibroblasts6 and CD34 stem cells,27 we
observed that CCN1 has an early migration-supporting effect
on monocytes. Preincubation with CCN1, however, com-
pletely abrogated not only the migration-stimulating effect of
CCN1 but also the chemotactic response to MCP-1, MIP-1,
and SDF-1. Of interest, CCN1 suppressed cardiac immune
cell infiltration strongly, both in the autoimmune and the MI
model, consistent with the assumption of direct blockade of
circulating monocytes by CCN1. Such a mechanism of
action, also supported by the in vitro transwell data, would be
essentially independent of specific local processes (eg, che-
mokine/cytokine patterns), which vary depending on the type
of injury (ischemic, autoimmune, viral, or gene defect).
Beyond the present study’s delineation of CCN1 as a novel
immune cell migration modulator, differential effects of
CCN1 dose and timing with respect to disease course need to
be evaluated further in the future. We also currently do not
know whether there are different effects of CCN1 on the
migration of immune cell subpopulations in vivo. In the trans-
well assays, cell proliferation did not influence the results, but in
vivo, T cells may proliferate locally in the heart after immigra-
tion in response to antigen, whereas monocytes do not. This,
along with the fact that the overwhelming fraction of heart-
infiltrating cells in EAM are monocytes, may explain the
Figure 5. cRGD peptides are partially CCN1-mimetic drugs. A, CCN1, SDF-1), and MCP-1 at 200 ng/mL are chemotactic for mono-
cytic THP-1 cells. Graph on the left shows the influence of CCN1 preincubation and graph on the right shows the influence of cRGD
preincubation on these chemotactic processes. Preincubation for 1 hour or 24 hours with 200 ng/mL CCN1 (CCN1-Pre; left) or cRGD
(cRGD-Pre; right) resulted in significant abrogation of the chemotaxis-stimulating effects of CCN1, SDF-1, and MCP-1 compared with
reference cells without preincubation (left bars in each triplet, designated “0”). All comparisons are based on separate cell samples
obtained at baseline. Two of the samples (1 hour, 24 hours) were preincubated with 200 ng/mL CCN1 (left graph) and another 2 with
10 mol/L cRGD (right graph). Neither CCN1 nor cRGD was added to the reference. For each preincubated group (CCN1 and cRGD,
respectively), 1 of the cell samples was analyzed after 1 hour and the other after 24 hours. Comparable results were obtained for 1
hour or 24 hours of preincubation with CCN1 protein or cRGD peptide (n9 to 12). P values on top of each triplet indicate Kruskal-
Wallis test results for the 6 experimental groups (for chemokines CCN1, SDF-1, MCP-1), each comprising cells without preincubation
or with preincubation for 1 hour or 24 hours. Asterisks indicate significant effects of preincubation on the corrected significance level
corr0.0167, with Pcorr0.05 (*), P0.01 (**), and Pcorr0.001 (***), respectively, according to Mann–Whitney U test for independent
samples with Bonferroni adjustment for multiple testing. B, Dose dependency of cRGD preincubation is shown for 0.1, 1.0, 10, and
100 mol/L cRGD peptide on THP-1 cells stimulated with 200 ng/mL CCN1, SDF-1, and MCP-1, respectively. The migration-
promoting effect of all 3 chemokines was inhibited over a broad dose range of cRGD. Inhibition of SDF-1–induced migration by cRGD
preincubation appears to be less pronounced than that by preincubation with CCN1 under these in vitro conditions (gray bars). n6/9.
P value on top of the SDF-1 graph indicates Kruskal-Wallis test result for the 6 experimental groups shown. Asterisk in the SDF-1
graph indicates a difference on the corrected significance level corr0.001, with Pcorr0.05 according to Mann–Whitney U test with
Bonferroni adjustment for multiple testing. IQR indicates interquartile range.
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unchanged cardiac expression of the T-cell cytokines
interleukin-17 and interferon- despite reduce immune cell
infiltration.
CCN1 Action on Immune Cells Is Mimicked in
Part by cRGD Peptides
Importantly, the in vitro transwell migration experiments as
conducted do not involve any immune cell–endothelium
interactions but reflect direct effects of CCN1 on the immune
cells themselves. Clearly, under such in vitro conditions, it is
the direct interaction of CCN1 with 1 or more of the known
receptors on the immune cells that results in their “repro-
gramming” by prolonged exposure. This must be assumed to
occur also in vivo during CCN1 therapy. Given the fact that
CCN1 is an evolutionary highly conserved endogenous pro-
tein, the biphasic profile is likely to confer important homeo-
static functions, including an optimized response of inflam-
matory effector cells to tissue injury. It is tempting to
speculate as to whether CCN1 can also result in systemic
depression of migration under pathophysiological conditions,
but that question is beyond the scope of this therapy-directed
report and requires additional studies. Likewise beyond its
scope is a full elucidation of the mechanism by which CCN1
modulates immune cell migration at the molecular and
cellular level. Global Western blot analyses (Figure 4D) were
unable to detect intracellular polarization processes39,40
known to determine the dynamic transitions between immo-
bile state, random migration, and directed migration (chemo-
taxis, haptotaxis) of immune cells. Instead, life-cell micros-
copy will be required for a detailed description of CCN1 and
cRGD peptide effects on these processes. Nevertheless, the
present data already indicate that both random migration
(Figures 2D and 4A) and directed migration along a chemo-
tactic gradient (Figures 4B, 4C, and 5) are affected by these
agents. At the systemic level, it will be interesting to
determine whether CCN1 treatment influences the generation
of T-cell responses and the ability of antigen-presenting cells
to migrate to draining lymph nodes.
Because CCN1 is known to exert part of its function by
binding to various integrins, we sought to compare its effect
on immune cell migration with that of the integrin-binding
cRGD peptides currently developed as antiangiogenic and
antiproliferative agents for cancer therapy.29,36 With respect
to our comparison of cRGD peptides with CCN1 (Figure 5B),
it is of interest that these synthetic compounds bind selec-
tively to one type of integrins only, whereas the complex,
4-domain protein CCN1 binds to a broad spectrum of
integrins, including 61, v3, v5, and M2, and to
heparan sulfate proteoglycans.41 Remarkably, direct compar-
ison of CCN1 with an integrin-interacting cRGD peptide
nevertheless showed a similar migration-inhibiting effect,
although chemotaxis toward SDF-1 was not blocked as
efficiently as with CCN1. Thus, the present studies describe
a novel migration-inhibiting effect for cRGD peptides, which
may be of considerable relevance for both anticancer and
antiinflammatory treatment. Chronic CCN1 exposure modi-
fies the immune cell response to a broad spectrum of
chemotactic stimuli in vitro and in vivo, in contrast to specific
chemokine or chemokine receptor–blocking agents21 with
their known limitations42 that arise from the fact that in most
inflammatory diseases, multiple chemokines and chemokine
receptors are involved, and no single target of outstanding
pathogenetic importance exists. Although the chemokine target
spectrum of CCN1 appears to be broader, evaluation of cRGD
peptides for immunomodulation and the treatment of inflamma-
tory diseases appears warranted on the basis of these data.
Possible Implications for the Treatment of
Cardiac Diseases
Different antiinflammatory therapeutic strategies are required
for distinct target diseases,43 and CCN1 may expand the
spectrum of tools for chemotaxis modulation and offer new
therapeutic perspectives for important cardiac44–46 and auto-
immune30,47 disorders. Therapeutic interest in CCN1 was
initially triggered by a genomics study in humans,1 which
resembles the path of other investigations that have used
genomic approaches to drive novel compound pipelines.48
Before any antiinflammatory approach is undertaken, it will
be crucial to delineate the distinction between acute inflam-
mation that supports tissue repair and regeneration versus
chronic inflammation without reparative advantage but that
induces progressive tissue injury. With respect to the latter
type of inflammation, further investigation of CCN1 as a new
parent compound for immune cell migration modulation
appears warranted, as well as of cRGD peptides as a first
class of partially CCN1-mimetic drugs with immediate po-
tential for clinical evaluation in cardiac disorders associated
with chronic pathogenic inflammation (eg, autoimmune heart
disease and cardiac transplant rejection).
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CLINICAL PERSPECTIVE
CCN1 is an evolutionary ancient matricellular protein that modulates biological processes associated with tissue repair.
Here, we provide evidence of a novel function of CCN1 as a modulator of immune cell migration, with therapeutic potential
in diseases associated with chronic pathogenic inflammation. In the current proof-of-concept study, we used CCN1 gene
transfer to evaluate its therapeutic potential in animal models of human inflammatory cardiomyopathy and myocardial
infarction. CCN1 therapy significantly reduced immune cell infiltration in both models. CCN1 exposure resulted in
strongly suppressed migration of immune cells both in vivo and in vitro and abrogated their chemotactic response to
various chemokines. These data suggest that CCN1 has potential as a new broad-spectrum immune cell migration inhibitor,
in contrast to specific chemokine- or chemokine receptor–blocking agents with their known limitations arising from the
fact that in most inflammatory diseases, multiple chemokines and chemokine receptors are involved and no single target
of outstanding pathogenic importance exists. From a clinical translational perspective, it is of interest that the effects of the
endogenous protein CCN1 on immune cell chemotaxis and migration are partially mimicked by cyclic RGD peptides that
are currently being evaluated in clinical trials, although as yet for cancer therapy only. Our proof-of-concept study suggests
further investigation of CCN1 as a new parent compound for immune cell migration modulation and of cyclic RGD
peptides as CCN1 mimetics with immediate potential for clinical evaluation in cardiac diseases associated with chronic
pathogenic inflammation.
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Cell Cultures and Proteins  
Eahy.926 cells were cultured in DMEM (Dulbecco's Modified Eagle) medium with Glutamax-I 
(Invitrogen, San Diego, CA USA), 10% fetal calf serum (FCS) and 1x HAT. Mouse splenocytes were 
cultured in RPMI 1640 supplemented with 5% FCS, THP1 with 10% FCS. Peripheral blood 
mononuclear cells (PBMCs) of healthy human donors (male and female aged 25 to 50) were cultivated 
in IMDM (Iscove’s Modified Dulbecco’s Medium) supplemented with 10% AB serum. The study was 
reviewed and approved by the Institutional Ethics Committee and informed consent was obtained from 
the patients. All cell culture media contained 1% penicillin/streptomycin. The proteins SDF1α (R&D 
Systems, Minneapolis, MN USA), MCP1 (Invitrogen, San Diego, CA USA), MIP1α (Invitrogen, San 
Diego, CA USA), and CCN1 (Cell sciences, Canton, MA USA) were used at 200 ng/mL. for 
stimulation. cRGD peptide (H4772, Bachem, Bubendorf, Switzerland) was used at 10 µM for 
preincubation.   
 
Development of Adenoviral CCN1 Vectors  
A full-length murine CCN1-cDNA was amplified from the expression plasmid pAdTrackCMV as a PCR 
product by using the primer-linkers mCyr61-1s-EcoRI (5´-cta gaa ttc atg agc tcc agc acc ttc agg acg-
3´) and mCyr61-BamHIas (5´-gct gga tcc tta gtc cct gaa ctt gtg ga-3´) which amplify NM_010516 
sequence nucleotides 194-1333. This product was directionally cloned into the adenovector transfer 
plasmid pZS2 digested with EcoRI and BamHI. Subsequently the recombinant plasmid pZS2-mCCN1 
was digested with Xba I and ligated to the long arm of the adenovirus strain RR5 as described 1 2. The 
ligation product was transfected into HEK293 cells and a recombinant adenoviral clone AdV-CMV-
mCCN1 was then amplified and purified by CsCl ultracentrifugation. For the development of the HA-
tagged CCN1 vector (HA = hemagglutinin epitope YPYDVPDYA from influenza virus A), CCN1 full-
length cDNA was amplified from mouse muscle RNA, after reverse transcription with random primers 
(Superscript II, Invitrogen, San Diego, CA USA), by using the primers #874 mCCN1-forw (5’-cgt  cat 
gaa ttc acc atg agc tcc agc acc ttc ag-3’) and #875 mCCN1-rev (5’-cgt cat gtc gac tta gtc cct gaa ctt 
gtg gat gt-3’). The amplification product was cloned into the pRK5 plasmid. CCN1-HA was then 








amplified as a PCR-Product by using the primers #874 mCCN1-forw and #876 mCCN1-HA-rev (5’cgt 
cat gtc gac tta agc gta gtc tgg gac gtc gta tgg gta gtc cct gaa ctt gtg gat gtc-3’) and cloned into pJet1.2 
(Invitrogen, Karlsruhe, Germany). pJet1.2-mCCN1-HA was digested with EcoRI and Sal I and 
mCCN1-HA was cloned into pRK5. pRK5-mCCN1-HA was digested with EcoRI and KpnI and CCN1-
HA was cloned into the adenovector transfer plasmid pZS2.    
 
CCN1 Vector Evaluation in Cell Cultures  
The endothelial Eahy.926 cell line was cultured in 6-well-plates with 5x105 cells per well in 3 mL 
DMEM medium with Glutamax-I, 10% fetal calf serum, 1% penicillin, 1% streptomycin, and 1xHAT. 
Cells were transduced after 24h with 3x103 particles of vector AdV-CMV-mCCN1 per cell. 72h later 
cell protein was isolated and culture supernatants collected and both analyzed by Western blot using a 
polyclonal sheep-anti-mouse-CCN1 primary antibody (R&D Systems, Minneapolis, MN USA) in 1:200 
dilution and a polyclonal secondary rabbit-anti-sheep-Ig/HRP antibody (Dako, Glostrup, Denmark) in 
1:1000 dilution. The antibodies detect recombinant mouse CCN1, but not endogenous human 
Eahy.926-derived or bovine fetal calf serum-derived CCN1. Human and bovine CCN1 were detected 
instead using a biotinylated polyclonal-goat-anti-CCN1 antibody (Santa Cruz, Santa Cruz, CA. USA) in 
1:200 dilution at 4°C overnight, followed by streptavidin/HRP conjugate (Millipore, Billerica, MA USA) 
at 1:1000 dilution at room temperature for 1h.  
CCN1 Gene Transfer in vivo  
For the murine autoimmune myocarditis model, 3x1010 particles/ mouse of AdV-CMV-mCCN1 or RR5 
vector were injected via tail vein into female BALB/c mice 1 week prior to immunization with MyHC-α. 
AdV-CMV-mCCN1-HA or RR5 vector were injected i.v. in the same doses, into 10 week old mice. For 
the myocardial infarction (MI) model, AdV-CCN1 or AdV-RR5 were also injected i.v. 4 days prior to MI 
induction into male C57B/6 mice.  
Analysis of Circulating CCN1 Protein  
Circulating CCN1 was studied by Western blot of mouse serum proteins after albumin depletion of the 
serum by ethanol precipitation. To deplete albumin, NaCl was added to ice-cold sera to a 
concentration of 0.1 M and the samples were then continuously shaken for 60 min. Ice-cold 95% 








ethanol was then added to a concentration of 42%. After incubation for 1h at 4°C these samples were 
centrifuged for 45 min at 13.000 rpm. The pellet was finally re-dissolved with 8M urea /2M thiourea 3. 
Circulating CCN1 in heparin plasma of AdV-CCN1-HA-treated, RR5-treated, and non-treated mice 
was analyzed by ELISA (DGR Diagnostics, Marburg, Germany) according to the manufacturer’s 
instructions. 
Tracking of Ad-CCN1-HA in vitro and ex vivo  
The endothelial Eahy.926 cell line was cultured in 6-well-plates with 3x105 cells per cell in 3 mL DMEM 
medium with Glutamax-I, 10% fetal calf serum, 1% penicillin, 1% streptomycin, and 3x105 Eahy.926 
cells were transduced after 24h with 3x103 particles of vector AdV-CMV-mCCN1 per cell. Brefeldin A 
was added after 48h at 7.5 ng/mL for intracellular staining. After 72h cells were harvested and stained 
for FACS analysis with anti-HA-FITC antibody (Miltenyi, Bergisch-Gladbach, Germany). For FACS 
analyses, livers, spleens. hearts, and blood PBMCs generated by Ficoll gradient of AdV-CCN1-HA 
vector-transduced mice and non-transfected control mice were taken on day 25. Single-cell 
suspensions from all organs were suspended in FACS buffer (PBS supplemented with 2% 
Flebogamma) and analysed by flow cytometry using a FACS Canto II analyzer (Beckton Dickinson, 
Franklin Lakes, NJ USA) and α-HA-FITC antibody or anti-mouse IgG1 isotype control (FITC) (Miltenyi, 
Bergisch-Gladbach, Germany). Surface staining was done for extracellular molecules CD11b, CD3e, 
CD11c, B220, and pan NK cells, respectively (eBioscience, San Diega, CA USA). 
 
Induction of Murine Autoimmune Myocarditis  
Vectors were injected i.v. into BALB/c mice (female) one week before their immunization with MyHC-α 
peptide. Immunization was then conducted by injection of MyHC-α peptide together with CFA, on days 
0 and 7. Control mice received 100 µg MyHC-α/CFA only. All analyses were performed at the peak of 
inflammation occurring 21 days post MyHC-α/CFA immunization. Myocarditis severity score was 
assessed on hematoxylin-eosin sections and graded from 0 to 4. Histological grading followed a well-
established semi-quantitative score from 0 to 4 (0: no inflammatory infiltrates; 1: small foci of 
inflammatory cells between myocytes; 2: larger foci of 100 inflammatory cells; 3: more than 10% of a 
cross section involved; and 4: more than 30% of a cross section involved).  









Induction and Analysis of Murine Myocardial Infarction  
Myocardial infarction (MI) was induced by coronary artery ligation as described 4 and mice were 
sacrificed 14 days later. Infarction was evident from discoloration of the left ventricle (LV). For 
histological analysis, hearts were fixed and sectioned (4 µm) and CD45-staining was performed to 
evaluate the number of leukocytes that had infiltrated the infarcted LV. CD45+ cells in the infarcted 
area were counted and residual necrotic area (characterized by presence of necrotic cells without 
evidence of local clearance, collagen deposition, and fibrosis) was calculated planimetrically as 
percent of this area.  
 
RNA Analyses 
The stability of AdV-mCCN1 expression in vivo was tested in mouse livers, after i.v. injection of 3x1010 
vector particles/animals (p/a), by Northern blots hybridized with an anti-bGH probe selective for 
recombinant mCCN1-mRNA  over a period of 40 days in mice injected with the vector AdV-mCCN1, 
RR5, and untreated animals (probe: sense: bgH 134s-NotI: gtt ctt gcg gcc gct tcg ata agc ta; 
antisense: bgH 418as-XbaI-ClaI-EcoRI: atc tct aga tcg atg ttt gaa tct ccc agc tgg ttc ttt cc). For 
quantification versus ß-Actin, Scion Image Gelplot2 software (Scion Corporation, Frederick, MD USA) 
was used. Total RNA extraction from mouse hearts, reverse-transcription (RT) reaction and Real Time 
PCR was performed to analyse the cytokines IFN-γ, IL17A, the chemokines MIP-1α and MCP-1, and 
the surface molecules CD3 and CD14 (see Supplemental Figure 3), respectively (Taqman Gene 
Expression Assay, Applied Biosystems, Foster City, CA USA).  RT PCR was performed for hearts of 
non-treated mice, mice that received MyHC-α/CFA alone, and mice that received MyHC-α/CFA and 
either AdV-mCCN1 or RR5 vector. Expression levels were compared to HPRT Expression. Hearts 
were taken at peak of inflammation. 
 
Migration Assay with Mouse Primary Cells  
Single cell suspensions were made from spleens of RR5 transfected and CCN1 transfected BALB/c 
mice. Erythrocytes were lysed using ACK buffer. Splenocytes were cultured in RPMI 1640 
supplemented with 5% FCS, 1% each of penicillin and streptomycin and 2% of glutamin and added to 








the upper well of 8 µm Transwell Permeable Supports (Corning, Corning, NY USA). Cells were 
incubated at 37°C, 5% CO2 for 24h. Cells in lower chamber were harvested, stained for CD11b and 
CD3e, and resuspended in 100 µL PBS +2% Flebogamma. 30 µL of 1:10 dilution of polystyrol beads 
(Comp Beads, neg control, BD, San Diego, CA USA) were added to each approach. Counting was 
performed by FACS analysis by gating on the bead population and uptake of exactly 20.000 beads per 
approach. Counted was the number of cells that were collected in parallel after excluding the bead 
population. Increase was estimated as ratio to control samples without stimulation. Dead cells were 
estimated by gating strategy.  
 
Migration Assay with Human Primary Cells and THP-1 
PBMCs of healthy human donors (male and female aged 25 to 50) were cultivated in IMDM 
supplemented with 10% AB serum, 1% each of penicillin and streptomycin. 37°C, 5% CO2. Lower 
wells of 96-well transwell (Corning, Corning, NY USA) contained 235 µL of IMDM medium +10% AB 
serum alone or additionally 200 ng/mL MCP-1 (Invitrogen, San Diego, CA USA), MIP-1α (Invitrogen, 
San Diego, CA USA) or CCN1 (Cell sciences, Canton, MA USA). 75 µL of 1.5x105 PBMCs from 
healthy human donors purified by Ficoll gradient were suspended in culture medium +10% AB serum 
and added to the upper well. Cells were incubated at 37°C, 5% CO2 for 42h. Cells in lower chamber 
were harvested, stained for CD14 (BD Pharmingen, San Diego, CA USA) and proceeded as described 
before. Furthermore, experiments were done with untouched sorted CD3+ T cells (CD3 depletion kit, 
Miltenyi, Bergisch-Gladbach, Germany) and adhesion enriched CD14 expressing monocytes from 
human PBMCs. CCN1 Preincubation: In pre-incubation experiments cells were stimulated with 
recombinant human CCN1 for 24h, then washed and re-stimulated as described above. The in vitro 
chemotaxis assay with THP-1 cells was performed as describes for primary cells. Cells in lower 
chamber were not harvested here, but incubated with MTT (tetrazolium-bromide) 5 mg/mL (Sigma, 
Munich, Germany) in a 1:10 dilution for 4h at 37°C. The 0,04N HCL in isopropanol was added 1:1 into 
the lower well to dissolve the dark blue crystals. Plates were read at a wavelength of 570 nm against 
blank without cells and migration was calculated at ratio to unstimulated cells. 
 








Pharmacological Inhibition of CCN1- and Chemokine-Related Signaling Pathways 
For the experiments shown in the Supplemental Figure 1 a series of drug inhibitors of cellular signaling 
pathways was evaluated in THP-1 cells. Acute (black bars ”CCN1”) vs prolonged (grey bars “CCN1 + 
24h Pre”) CCN1 exposure was compared. Further comparison include Ly294.002, a phosphoinositide 
3-kinase (PI3K) inhibitor at 10 µM concentration 5; Triciribin, an AKT inhibitor at 10 µM 6; a Rho-kinase 
inhibitor at 10 µM 7; PD98059, a MEK inhibitor at 50 µM 5; a specific inhibitor of PI3Kγ 8; and two 
cyclo-RGD peptides (cRGD1, cRGD2) inhibiting αv integrins 9 at 100 µM concentration. 
 
Western Blots  
Signal transduction in THP-1 cells was examined by incubation of THP-1 cells for 0 min, 5 min, 30 
min, 3h, 8h and 24h either with MCP-1 (Invitrogen, San Diego, CA USA) and additionally with 24h 
CCN1 (Cell sciences, Canton, MA USA) preincubation (24h Pre) and afterwards MCP-1 stimulation for 
indicated time points. Cells were solubilized in general lysis buffer (20 mM Tris, pH 8, 10 mM NaCl, 
0.5% (v/v) Triton X-100, 5 mM EDTA, 3 mM MgCl2). After boiling of 30 µg, estimated by BCA method 
(BCA™ Protein Assay Kit (Thermo Scientific, Schwerte, Germany) of the lysate at 95°C for 5 min, 
proteins were separated on NuPAGE 4–12% Bis–Tris gels (Invitrogen, San Diego, CA USA) under 
denaturing and reducing conditions and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, 
USA). SeeBlue®Plus2 Prestained (Invitrogen, San Diego, CA USA) was used as standard. 
Membranes were incubated with the primary antibodies mouse-α-GAPDH (Millipore, Billerica, MA 
USA), mouse-α-Nck2 1:500 (Abnova, Neihu District. Taipei City Taiwan), mouse-α-PINCH 1:1000 (BD 
Biosciences San Diego, CA USA), mouse-α-ILK 1:1000, AKT, and pAKTS472/473 (1:500)  (BD 
Biosciences, San Diego, CA USA). The primary and the secondary antibody goat-α-mouse Ig-HRP 
1:2000 (Dako, Glostrup, Denmark) were incubated for 1h or overnight in dry milk. Detection by 
chemiluminescence was achieved by using an enhanced chemiluminescence system (Rodeo™ ECL 
Western Blot Detection kit) (USB Crporation, Cleveland, OH USA). Quantification versus GAPDH was 
performed by Scion Image Gelplot2 software (Scion Corporation, Frederick, MD USA) (see 
Supplemental Figure 2). 
 
 








Chemokine Receptor Expression 
PBMCs were either left untreated or stimulated with recombinant human CCN1 protein at 200 ng/mL 
for 24h. Cells were harvested, stained extracellularly for CCR2, CCR5, and CXCR4, respectively, and 
analyzed by gating for lymphocyte and monocyte populations by FACS comparing the median 
fluorescence intensities.  
 
Statistical Analyses  
Statistical data analyses were done using the software SPSS 18.0 (SPSS Inc. Chicago, IL USA). 
Nonparametric statistical methods were used. Continuous variables were expressed as median and 
interquartile range, if not indicated otherwise. Univariate comparisons of two independent groups were 
done using the Mann-Whitney-U test. Confirmatory analyses concerning more than two groups were 
performed by using the Kruskal-Wallis test, followed by post hoc testing via Mann-Whitney U test with 
Bonferroni adjustment for multiple testing. To compare between two paired groups, the Wilcoxon sign-
rank test was applied. Due to small sample sizes, calculations were done using exact assumption 
methods (option “exact” in PASW 18.0). A two-tailed p-value of <0.05 was considered statistically 
significant. 
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Supplemental Figures 
 
Supplemental Figure 1 
 
A. Monocytic THP-1 cells were stimulated for 24h either directly with 200 ng/mL of CCN1, (grey bar) or 
after 1h of pre-incubation with 200 ng/mL CCN1 (CCN1-Pre),  the PI3K inhibitor Ly294_002 at 10 µM, 
PI3Kγ inhibitor at 10 µM, the Akt inhibitor Triciribin at 10 µM, Rho kinase / ROCK  inhibitor at 10 µM, 
MEK inhibitor PD98059 at 50 µM, and cRGD peptide 1 at 100 µM (H4772) and cRGD peptide 2 at 100 
µM (H2574), respectively.  
B, C, D show the data from analogous experimental settings using stimulation with SDF-1α (panel B), 
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Supplemental Figure 2 
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Figure Legend: Intracellular signal transduction proteins linked to integrins and AKT phosphorylation 
were analyzed by Western blot. The black curves show THP-1 protein expression levels of ILK, NCK2, 
PINCH, and β-arrestin 2 that blocks G protein-mediated signaling, at various time points (5 min, 30 
min , 3h , 8h , and 24h) after addition of 200 ng/mL MCP-1. The red curves show similar analyses, but 
with addition of the MCP-1 after a preceding preincubation with CCN1 at 200 ng/mL for 24h (shown is 
one of at least two independent experiments). Protein expression levels of ILK, β-arrestin, PINCH, and 
Nck2 were referred to GAPDH. Expression level of pAKTS472/472 was referred to GAPDH and total AKT, 
respectively. Quantification was performed by Scion Image Gelplot2 software. Densitometric analysis 
showed that MCP-1 induced, as expected, upregulation of ILK, β-arrestin, PINCH, and pAKTS472/473, 
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Figure Legend: RT-PCR of mice heart tissues was performed to analyze the surface molecules CD3  
(panel A) and CD14 (panel B) characterizing infiltrates of T cells and monocytes/macrophages, 
respectively. RT-PCR was performed for hearts of non-treated mice (NT), mice that received MyHC-
α/CFA alone (NT/MyHC-α/CFA), and mice that received MyHC-α/CFA plus either AdV-CCN1 (CCN1) 
or RR5 (RR5) vector. The expression levels were compared to HPRT expression. Hearts were taken 
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